Bevacizumab in advanced lung cancer: state of the art

Assoun, Sandra; Brosseau, Solenn; Steinmetz, Christelle; Gounant, V.; Zalcman, Gérard

doi:10.2217/fon-2017-0302

Cited by 50 publications

(42 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, antiangiogenesis therapy plays an important role in oncotherapy. However, bevacizumab was approved only for nonsquamous NSCLC . Nintedanib prolonged overall survival (OS) only in patients with ACC .…”

Section: Introductionmentioning

confidence: 99%

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Cheng

Han

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Background: Anlotinib showed significant survival benefits in advanced nonsmall cell lung cancer (NSCLC) patients as a third-or further-line treatment in the ALTER0303 trial. We aimed to evaluate the efficacy of anlotinib in patients with different histologies. Methods: The ALTER0303 trial was a randomized, open-label, phase 3 study of anlotinib in NSCLC patients previously treated with at least two lines of chemotherapy or a tyrosine kinase inhibitor (TKI) in 31 centers in China. Patients were randomly assigned at a 2:1 ratio to receive anlotinib (12 mg QD from days 1 to 14 of a 21-day cycle) or placebo until progression or intolerable toxicity. The primary endpoint was overall survival (OS). We assessed the efficacy of anlotinib in histological subgroups in the full analysis set. |CHENG Et al.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Cheng

Han

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…This study revealed promising antitumor synergy and a high MPE control rate after treatment with bevacizumab plus chemotherapy. One of the probable mechanisms of the synergistic effect of bevacizumab plus chemotherapy is based on the theory of bevacizumab‐induced tumor vascular normalization, which is considered to decrease tumoral interstitial hypertension, subsequently enhancing efficacious delivery and the uptake of drugs . A study from China showed that the use of paclitaxel and bevacizumab enhances the treatment effect in NSCLC patients with MPE .…”

Section: Discussionmentioning

confidence: 99%

“…One of the probable mechanisms of the synergistic effect of bevacizumab plus chemotherapy is based on the theory of bevacizumab-induced tumor vascular normalization, which is considered to decrease tumoral interstitial hypertension, subsequently enhancing efficacious delivery and the uptake of drugs. 20 A study from China showed that the use of paclitaxel and bevacizumab enhances the treatment effect in NSCLC patients with MPE. 17 Qi et al reported that T1/2a (hour) of paclitaxel in pleural fluid samples were 4.58 AE 0.45 and 0.83 AE 0.05 in paclitaxel and paclitaxel/bevacizumab-treated patients, respectively (P < 0.01).…”

Section: Discussionmentioning

confidence: 99%

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion

Hong

Meng

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundVEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy containing bevacizmab was investigated in patients with lung adenocarcinoma‐induced MPE.MethodsThe data of lung adenocarcinoma patients with MPE treated with bevacizumab plus chemotherapy on day 1, every three weeks, for ≤ 6 cycles was retrospectively collected. Patients who achieved a response or stable disease were administered bevacizumab as maintenance therapy until progression. The primary outcomes of the study were MPE response rate (RR), MPE control rate, and pleural progression‐free survival (PPFS), while the secondary outcomes were PFS, overall survival (OS), changes to the lung volume and thoracic cage, and safety profiles.ResultsA total of 21 cases were collected, and all were evaluable for response, including 15 chemotherapy‐naïve patients and 6 who experienced relapse. The median cycle of treatments was 7 (1‐42) and 5 (2‐6) for bevacizumab and chemotherapy, respectively. The MPE RR reached 81.0%. The MPE control rate at 6, 12, 24, 48, and 96 weeks were 95.2%, 90.0%, 89.5%, 73.7%, and 43.8%, respectively. Median PPFS was significantly longer than PFS (22.2 vs. 7.8 months; P = 0.044), and median OS was 25.8 months. Nineteen (90.5%) patients experienced lung re‐expansion after treatment. Only one (4.8%) patient suffered thoracic volume decrease during treatment and the follow‐up period. No unexpected adverse events were observed.ConclusionsBevacizumab combined with chemotherapy demonstrated efficacious, persistence, and safety in controlling lung cancer‐induced MPE, indicating a potential superior therapeutic option.

show abstract

“…Bevacizumab is another monoclonal antibody (humanized) that blocks the VEGF and interferes with its binding to its receptors. Thus, it inhibits angiogenesis, which is an essential process for the development of new blood vessels to supply cancer cells with oxygen and nutrients [120]. Bevacizumab showed productive anticancer activities against colorectal, kidney, lung, breast and head and neck cancers [111].…”

Section: Immune Therapies: Bevacizumab As An Examplementioning

confidence: 99%

COVID-19 Pandemic: an Overview of epidemiology, pathogenesis, Diagnostics and Potential Vaccines and Therapeutics

et al. 2020

View full text Add to dashboard Cite

At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand. Graphical abstract:

show abstract

Bevacizumab in advanced lung cancer: state of the art

Cited by 50 publications

References 103 publications

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion

COVID-19 Pandemic: an Overview of epidemiology, pathogenesis, Diagnostics and Potential Vaccines and Therapeutics

Contact Info

Product

Resources

About